Picamilon.
GABA plus niacin. Russian brain circulation formula.
Reviewed March 2026
- Category
- Amino acid
- Also filed under
- AnxietyFocusBlood flow
What Picamilon is, and what it does.
- Does it work
- Suits people who already use GABA or niacin separately and want them delivered as one joined molecule. Human research is thin at 56 records, mostly older and from one research tradition.
- How much to take
- Start with 50 to 150mg a day as a single daytime dose. That band reflects how the conjugate has been used rather than a deep body of dose-finding work.
- Time to feel it
- If the niacin half produces a flush, that lands within twenty to thirty minutes. Any calmer feeling takes about an hour, and only 56 records exist to describe it.
- The first dose
- Day one can bring a warm, tingling flush from the released nicotinic acid within half an hour. Beyond that, most descriptions are of a mild settling rather than anything sharp.
- With regular use
- Most effects take 2-8 weeks. Be patient.
- How well tolerated
- Generally well tolerated. Check with your doctor if on medications.
- How it feels
- Mild relaxation with mental clarity. Niacin flush possible.
- The overlooked benefit
- It's one joined molecule, not a blend, so GABA powder plus niacin powder is a different thing. Only an assay separates them, which makes the batch test worth asking about.
50 to 150mg a day is where Picamilon works.
Source: Russian pharmacological literature; Mirzoyan et al., 1989
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Based on 10 human trials with 60% consistency.
- a calm, settled mental stateNarrative review
- cerebral blood flowNarrative review
- delivery of GABA across the blood-brain barrierAnimal study
- hydrolysis to nicotinic acid and GABA in tissueAnimal study
- cutaneous vasodilation from the nicotinic acid halfRandomised trial
Questions people ask about Picamilon.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
- Who benefits most from this?
- Honestly, most people would benefit more from the basics. But if you've got a specific reason to try it, the risk is generally low.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Picamilon is nicotinoyl-GABA, and after crossing into the brain it is hydrolysed to free GABA plus nicotinic acid. Taking it alongside GABA feeds the same inhibitory pool, so the two are not independent inputs and doses should be counted together.
Hydrolysis of picamilon releases nicotinic acid, the same molecule niacin delivers, which acts on the prostaglandin-mediated cutaneous vasodilation pathway. Stacking the two raises the combined nicotinic acid load and makes warmth or flushing more likely.
The niacin half of picamilon is a vasodilator and vinpocetine widens cerebral vessels through phosphodiesterase and sodium channel effects. Both push in the same direction on cerebral perfusion, so the vasodilatory effect is cumulative.
Ginkgo acts on vascular tone and platelet signalling while picamilon's nicotinic acid moiety relaxes vessels directly. Stacking them raises the combined vasodilatory load.
Theanine modulates glutamate transmission and alpha activity while picamilon delivers GABA past the blood brain barrier. The calming effects layer on the same balance of excitatory and inhibitory tone.
Passionflower flavonoids act as positive modulators at GABA-A receptors while picamilon raises GABA availability itself. Agonist plus modulator on the same receptor system is additive.
Caffeine raises alertness by blocking adenosine receptors, which runs against the inhibitory tone picamilon's GABA half produces. The pairing is used to offset sedation rather than to reinforce it.
Picamilon releases nicotinic acid, which causes flushing through prostaglandin mediated vasodilation, whereas niacinamide supplies the same vitamin without that vascular effect. Swapping one for the other changes the vasodilatory part of the response, so they are not interchangeable in a blend.
Melatonin acts through circadian receptors and picamilon through inhibitory neurotransmission, but both reduce alertness. The sedative end point is shared, which matters for evening dosing.
Magnesium acts at the GABA-A receptor complex and also blocks the NMDA receptor channel pore, both of which push net signalling in the inhibitory direction. A molecule that delivers a GABA moiety works on the same receptor family. The pairing is mechanistic; no combination study exists.
Glycine is the other major fast inhibitory neurotransmitter in the central nervous system, acting at its own chloride-permeable receptor mainly in brainstem and spinal cord. GABA and glycine converge on the same functional outcome through separate receptors. Additive sedation is the relevant consideration when the two are stacked.
Taurine is a weak agonist at both GABA-A and glycine receptors and also influences chloride handling in neurons. That gives it overlapping pharmacology with any GABA-delivering compound. The overlap is documented receptor pharmacology rather than a trialled combination.
Valerian constituents interact with the GABA-A receptor complex and valerenic acid modulates the beta subunit. Stacking it with a compound designed to deliver GABA centrally is additive on the same axis. Additive sedation is the thing to watch, particularly around driving.
Rosmarinic acid and related constituents of lemon balm inhibit GABA transaminase, the enzyme that degrades GABA. Slowing that breakdown raises the persistence of GABA that is already present. Combining a supply-side and a breakdown-side approach is additive in principle and untested as a pair.
Chamomile carries apigenin, which binds the benzodiazepine site of the GABA-A receptor as a partial agonist. That is a modulatory position on the same receptor a GABA moiety activates. The combination is additive on sedation and has not been formally studied.
Apigenin occupies the benzodiazepine allosteric site rather than the orthosteric GABA site, so it changes the receptor's response to GABA rather than activating it directly. Pairing an allosteric modulator with a source of the agonist is a coherent mechanistic construction. Nothing has measured the two together.
Honokiol and magnolol are positive allosteric modulators at GABA-A receptors, a mechanism documented in receptor pharmacology work. That places them on the same axis as a GABA-delivering molecule. Additive sedation applies and no combination data exist.
Tryptophan is the dietary precursor for serotonin and downstream melatonin, a separate transmitter system from GABA. Formulas aimed at evening calm often stack the two systems. The routes are distinct and the pairing is formulation logic rather than measured synergy.
Extracts of ashwagandha have shown GABA-mimetic activity in receptor and animal work, alongside effects on cortisol measures in human trials. Stacking it with a GABA-delivering compound adds to the same axis. Cortisol is a marker and the combination has not been studied.
Picamilon releases nicotinic acid on hydrolysis, and nicotinic acid is one of the precursors feeding the NAD pool that nicotinamide riboside also feeds. The amounts contributed by a typical picamilon dose are small relative to a dedicated NAD precursor. Worth naming because it explains why the niacin half is not inert.
Hydrolysis of picamilon liberates nicotinic acid, the same molecule responsible for the cutaneous flush at higher niacin doses through prostaglandin D2 release in skin. Taking free nicotinic acid alongside adds to that total. This is straightforward additivity of one shared moiety.
Inositol supplies the backbone of the phosphoinositide second messenger system used downstream of several serotonin and other G protein-coupled receptors. That is a different node from a chloride-channel receptor. The pairing appears in calm-focused formulas on formulation logic rather than on combination evidence.
Alpha-GPC supplies choline for acetylcholine synthesis, which pushes toward arousal and attention rather than inhibition. Stacking it with a GABA-delivering compound sets two opposing directions in one formula. Naming the tension is more useful than calling it synergy.
Rhodiola tends toward alerting effects in human trials of fatigue measures, the opposite direction to an inhibitory compound. Some formulators pair them deliberately to blunt the edge of each. The interaction is directional opposition, not additive benefit, and has not been measured.
Bacopa is used for memory-related endpoints in human trials that run over weeks, a different time course from an acute calming compound. Blends combine the two on complementary timescales. There is no combination trial and the rationale is formulation practice.
Talk to a doctor before taking Picamilon if any of these apply to you: regulatory varies. These are flags to check first, not effects Picamilon is known to cause.
Not medical advice. Show the label to your pharmacist.What Picamilon actually does.
Picamilon is N-nicotinoyl-gamma-aminobutyric acid, a single molecule in which nicotinic acid and GABA are joined by an amide bond; it is not a blend of the two.
GABA is the principal fast inhibitory neurotransmitter of the mammalian central nervous system, acting at chloride-permeable GABA-A receptors and at metabotropic GABA-B receptors.
Free GABA crosses the blood-brain barrier poorly because it is a small zwitterion without a dedicated high-capacity transporter at the endothelium, which is the entire design rationale for conjugating it to a more lipophilic carrier.
Nicotinic acid causes cutaneous vasodilation through GPR109A activation on skin Langerhans cells and the prostaglandin D2 release that follows, which is the mechanism of the niacin flush.
Where Picamilon comes from.
It is built in a factory by chemically gluing niacin to GABA. Neither half is unusual on its own, and the glue is the whole point. The thing worth checking is whether a given powder is the actual joined molecule or just the two ingredients mixed together, because they are not the same and only an assay tells them apart.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
Both starting materials are ordinary bulk chemicals; nicotinic acid is produced by oxidation of alkylpyridines and GABA by fermentation or chemical synthesis
The acid is converted to a reactive derivative, typically the acid chloride or an activated ester, so that it will form an amide with the amine of GABA
The activated nicotinoyl group is condensed with the primary amine of GABA under basic conditions to form the N-nicotinoyl amide bond that defines the molecule
The crude product is crystallised and washed to remove unreacted starting materials, coupling by-products and residual solvent; free GABA and free nicotinic acid are the two impurities that matter most because both are pharmacologically active on their own
Content is set by HPLC against a reference standard with identity confirmed by spectroscopy; without that step a powder can be a physical mix of the two starting materials rather than the conjugate
The acid is neutralised to the sodium salt for solubility, dried, and packed under low humidity because the salt takes up moisture
Getting Picamilon from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
Problems people have reported.
Read this carefully. These are 62 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Picamilon is, not how risky it is. A report is not proof Picamilon caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.